Advanced Practice Providers Oncology Summit.

CRS/ICANS Unveiled: From Detection to Intervention

Overview

Participants will delve into advanced therapies in Chimeric Antigen Receptor (CAR) T-cell treatment, focusing on their ability to target specific antigens for cell activation and tumor cell eradication. The session will also address the complexities of managing Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), the most common toxicities associated with CAR T-cell therapy, highlighting the challenges these conditions pose in patient care.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Identify signs and symptoms of CRS/ICANS.
2. Review monitoring strategies for patients with CRS/ICANS
3. Discuss treatment and management options for CRS/ICANS.       

Faculty: Alex Evans, PharmD, BCOP

CREDIT HOURS: 0.50 AMA PRA Category 1 Credit™ 0.50 ANCC

Course Expires: 1.22.26

Similar Courses To Consider